메뉴 건너뛰기




Volumn 16, Issue 6, 2012, Pages 819-826

Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?

Author keywords

Erythropoiesis stimulating agents; Ferritin; Hepcidin; Iron; Renal anemia

Indexed keywords

ANTIANEMIC AGENT; CARRIER PROTEIN; DEVALENT METAL TRANSPORTER 1; FERRIC GLUCONATE; FERRITIN; FERROPORTIN; HEPCIDIN; IRON; IRON TRANSPORT PROTEIN; UNCLASSIFIED DRUG;

EID: 84876295741     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0694-3     Document Type: Review
Times cited : (45)

References (62)
  • 1
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    • 9718377 10.1056/NEJM199808273390903 1:CAS:528:DyaK1cXlvVyrtr8%3D
    • Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90.
    • (1998) N Engl J Med , vol.339 , pp. 584-590
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3    Egrie, J.C.4    Nissenson, A.R.5    Okamoto, D.M.6    Schwab, S.J.7    Goodkin, D.A.8
  • 2
    • 33751002326 scopus 로고    scopus 로고
    • Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    • CREATE Investigators 17108342 10.1056/NEJMoa062276 1:CAS:528: DC%2BD28Xht1Wqt7fM
    • Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-784.
    • (2006) N Engl J Med , vol.355 , pp. 2071-2784
    • Drueke, T.B.1    Locatelli, F.2    Clyne, N.3    Eckardt, K.U.4    MacDougall, I.C.5    Tsakiris, D.6    Burger, H.U.7
  • 3
    • 33750983605 scopus 로고    scopus 로고
    • Correction of anemia with epoetin alfa in chronic kidney disease
    • CHOIR Investigators 17108343 10.1056/NEJMoa065485 1:CAS:528: DC%2BD28Xht1Wqt7fN
    • Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
    • (2006) N Engl J Med , vol.355 , pp. 2085-2098
    • Singh, A.K.1    Szczech, L.2    Tang, K.L.3    Barnhart, H.4    Sapp, S.5    Wolfson, M.6
  • 5
    • 75149198323 scopus 로고    scopus 로고
    • Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    • 20035034 10.1681/ASN.2009111127
    • Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010;21:2-6.
    • (2010) J Am Soc Nephrol , vol.21 , pp. 2-6
    • Singh, A.K.1
  • 6
    • 79955958017 scopus 로고    scopus 로고
    • Hepcidin and iron regulation, ten years later
    • 21346250 10.1182/blood-2011-01-258467 1:CAS:528:DC%2BC3MXlvFKmu7g%3D
    • Ganz T. Hepcidin and iron regulation, ten years later. Blood. 2011;117:4425-33.
    • (2011) Blood , vol.117 , pp. 4425-4433
    • Ganz, T.1
  • 7
    • 77954249308 scopus 로고    scopus 로고
    • Two to tango: Regulation of Mammalian iron metabolism
    • 20603012 10.1016/j.cell.2010.06.028 1:CAS:528:DC%2BC3cXpt1Cjt7k%3D
    • Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142:24-38.
    • (2010) Cell , vol.142 , pp. 24-38
    • Hentze, M.W.1    Muckenthaler, M.U.2    Galy, B.3    Camaschella, C.4
  • 8
    • 84864285226 scopus 로고    scopus 로고
    • Hepcidin: Another culprit for complications in patients with chronic kidney disease?
    • 21785039 10.1093/ndt/gfr410 1:CAS:528:DC%2BC3MXhtlGqtr7F
    • Nakanishi T, Hasuike Y, Otaki Y, Kida A, Nonoguchi H, Kuragano T. Hepcidin: another culprit for complications in patients with chronic kidney disease? Nephrol Dial Transplant. 2011;26:3092-100.
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 3092-3100
    • Nakanishi, T.1    Hasuike, Y.2    Otaki, Y.3    Kida, A.4    Nonoguchi, H.5    Kuragano, T.6
  • 9
    • 0031780146 scopus 로고    scopus 로고
    • The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry
    • 9681705 10.1093/ndt/13.7.1642 1:STN:280:DyaK1czksFSgsg%3D%3D
    • Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13:1642-4.
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 1642-1644
    • Locatelli, F.1    Conte, F.2    Marcelli, D.3
  • 10
    • 9144264827 scopus 로고    scopus 로고
    • Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    • 14671047 10.1093/ndt/gfg458
    • Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121-32.
    • (2004) Nephrol Dial Transplant , vol.19 , pp. 121-132
    • Locatelli, F.1    Pisoni, R.L.2    Combe, C.3    Bommer, J.4    Andreucci, V.E.5    Piera, L.6    Greenwood, R.7    Feldman, H.I.8    Port, F.K.9    Held, P.J.10
  • 11
    • 33645474065 scopus 로고    scopus 로고
    • Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients
    • 16565261 10.1681/ASN.2005090997 1:CAS:528:DC%2BD28XjvFSqtrY%3D
    • Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181-91.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 1181-1191
    • Regidor, D.L.1    Kopple, J.D.2    Kovesdy, C.P.3    Kilpatrick, R.D.4    McAllister, C.J.5    Aronovitz, J.6    Greenland, S.7    Kalantar-Zadeh, K.8
  • 12
    • 33846669860 scopus 로고    scopus 로고
    • Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis
    • 17276778 10.1016/S0140-6736(07)60194-9 1:CAS:528:DC%2BD2sXht1OrsLY%3D
    • Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-8.
    • (2007) Lancet , vol.369 , pp. 381-388
    • Phrommintikul, A.1    Haas, S.J.2    Elsik, M.3    Krum, H.4
  • 13
    • 38449094145 scopus 로고    scopus 로고
    • Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets
    • 17942772 10.2215/CJN.02380607 1:CAS:528:DC%2BD2sXhtlGgsbfE
    • Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007;2:1274-82.
    • (2007) Clin J Am Soc Nephrol , vol.2 , pp. 1274-1282
    • Fishbane, S.1    Besarab, A.2
  • 14
    • 83655163838 scopus 로고    scopus 로고
    • Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: Results from a cohort study from the Dialysis Registry in Japan
    • Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S.: Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the Dialysis Registry in Japan. Am J Kidney Dis. 2012 59(1) 108-16.
    • (2012) Am J Kidney Dis. , vol.59 , Issue.1 , pp. 108-116
    • Fukuma, S.1    Yamaguchi, T.2    Hashimoto, S.3    Nakai, S.4    Iseki, K.5    Tsubakihara, Y.6    Fukuhara, S.7
  • 16
    • 77956255701 scopus 로고    scopus 로고
    • On behalf of the Anaemia Working Group of European Renal Best Practice (ERBP).: Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study
    • 20591813 10.1093/ndt/gfq336
    • Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A. On behalf of the Anaemia Working Group of European Renal Best Practice (ERBP).: target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrol Dial Transplant. 2010;25:2846-50.
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 2846-2850
    • Locatelli, F.1    Aljama, P.2    Canaud, B.3    Covic, A.4    De Francisco, A.5    MacDougall, I.C.6    Wiecek, A.7
  • 17
    • 79955024469 scopus 로고    scopus 로고
    • Iron supplementation to treat anemia in patients with chronic kidney disease
    • 20956992 10.1038/nrneph.2010.139 1:CAS:528:DC%2BC3cXhsVyhtbfP
    • Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010;6:699-710.
    • (2010) Nat Rev Nephrol , vol.6 , pp. 699-710
    • Besarab, A.1    Coyne, D.W.2
  • 18
    • 0035168242 scopus 로고    scopus 로고
    • Hyporesponsiveness to recombinant human erythropoietin
    • 11590253 10.1093/ndt/16.suppl-7.25
    • Drüeke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001;16:25-8.
    • (2001) Nephrol Dial Transplant , vol.16 , pp. 25-28
    • Drüeke, T.1
  • 19
    • 0032873161 scopus 로고    scopus 로고
    • Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit
    • 10516375 10.1053/ajkd.1999.v34.aajkd0344b0040 1:CAS:528: DyaK1MXntVCmtb8%3D
    • Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis. 1999;34:S40-6.
    • (1999) Am J Kidney Dis , vol.34
    • MacDougall, I.C.1    Chandler, G.2    Elston, O.3    Harchowal, J.4
  • 20
    • 0028535168 scopus 로고
    • Monitoring of iron status and iron supplementation in patients treated with erythropoietin
    • 7881986 10.1097/00041552-199411000-00010 1:STN:280:DyaK2M7oslOqsA%3D%3D
    • Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens. 1994;3:620-5.
    • (1994) Curr Opin Nephrol Hypertens , vol.3 , pp. 620-625
    • MacDougall, I.C.1
  • 22
    • 33846694048 scopus 로고    scopus 로고
    • Clinical aspects of iron use in the anemia of kidney disease
    • 17229908 10.1681/ASN.2006080856
    • Horl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007;18:382-93.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 382-393
    • Horl, W.H.1
  • 23
    • 0345099328 scopus 로고    scopus 로고
    • Intravenous iron as adjuvant therapy: A two-edged sword?
    • 10.1093/ndt/gfg1088
    • Cavill I. Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol Dial Transplant. 2003;18:24-8.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 24-28
    • Cavill, I.1
  • 24
    • 0023120533 scopus 로고
    • Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase i and II clinical trial
    • 3537801 10.1056/NEJM198701083160203 1:STN:280:DyaL2s%2FmsFSjsw%3D%3D
    • Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-8.
    • (1987) N Engl J Med , vol.316 , pp. 73-78
    • Eschbach, J.W.1    Egrie, J.C.2    Downing, M.R.3    Browne, J.K.4    Adamson, J.W.5
  • 25
    • 0024970849 scopus 로고
    • Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously
    • 2504356 10.1136/bmj.299.6692.157 1:STN:280:DyaL1MzltlSntg%3D%3D
    • Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989;299:157-8.
    • (1989) BMJ , vol.299 , pp. 157-158
    • MacDougall, I.C.1    Hutton, R.D.2    Cavill, I.3    Coles, G.A.4    Williams, J.D.5
  • 26
    • 9644295720 scopus 로고    scopus 로고
    • Safety of intravenous iron in clinical practice: Implications for anemia management protocols
    • Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol. 2004;2:99-106.
    • (2004) J Am Soc Nephrol , vol.2 , pp. 99-106
    • Aronoff, G.R.1
  • 27
    • 33947212276 scopus 로고    scopus 로고
    • Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study
    • 10.1681/ASN.2006091034
    • Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:97594.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 97594
    • Coyne, D.W.1    Kapoian, T.2    Suki, W.3    Singh, A.K.4    Moran, J.E.5    Dahl, N.V.6    Rizkala, A.R.7
  • 29
    • 0032934971 scopus 로고    scopus 로고
    • Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: A study using positron emission tomography
    • 10050711 10.1046/j.1365-2141.1999.01179.x 1:CAS:528:DyaK1MXhsV2gsbY%3D
    • Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, Antoni G, Langstrom B, Danielson BG. Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol. 1999;104:296-302.
    • (1999) Br J Haematol , vol.104 , pp. 296-302
    • Beshara, S.1    Lundqvist, H.2    Sundin, J.3    Lubberink, M.4    Tolmachev, V.5    Valind, S.6    Antoni, G.7    Langstrom, B.8    Danielson, B.G.9
  • 30
    • 77949726600 scopus 로고
    • Ferrokinetics in normal persons and in patients having various erythropoietic disorders
    • 14897912 10.1172/JCI102562
    • Huff RL, Elmlinger PJ, Garcia JF, Oda JM, Cockrell MC, Lawrence JH. Ferrokinetics in normal persons and in patients having various erythropoietic disorders. J Clin Invest. 1951;30:1512-26.
    • (1951) J Clin Invest , vol.30 , pp. 1512-1526
    • Huff, R.L.1    Elmlinger, P.J.2    Garcia, J.F.3    Oda, J.M.4    Cockrell, M.C.5    Lawrence, J.H.6
  • 31
    • 0030854921 scopus 로고    scopus 로고
    • Utilization of intracellular ferritin iron for hemoglobin synthesis in developing human erythroid precursors
    • 9226184 1:CAS:528:DyaK2sXksF2jtLw%3D
    • Vaisman B, Fibach E, Konijn AM. Utilization of intracellular ferritin iron for hemoglobin synthesis in developing human erythroid precursors. Blood. 1997;90:831-8.
    • (1997) Blood , vol.90 , pp. 831-838
    • Vaisman, B.1    Fibach, E.2    Konijn, A.M.3
  • 32
    • 0031028178 scopus 로고    scopus 로고
    • Tissue-specific regulation of iron metabolism and heme synthesis: Distinct control mechanisms in erythroid cells
    • 8978272 1:CAS:528:DyaK2sXhsFahuw%3D%3D
    • Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood. 1997;89:1-25.
    • (1997) Blood , vol.89 , pp. 1-25
    • Ponka, P.1
  • 33
    • 40349103525 scopus 로고    scopus 로고
    • Macrophages function as a ferritin iron source for cultured human erythroid precursors
    • 17902167 10.1002/jcb.21499 1:CAS:528:DC%2BD1cXjtVyntb0%3D
    • Leimberg MJ, Prus E, Konijn AM, Fibach E. Macrophages function as a ferritin iron source for cultured human erythroid precursors. J Cell Biochem. 2008;103:1211-8.
    • (2008) J Cell Biochem , vol.103 , pp. 1211-1218
    • Leimberg, M.J.1    Prus, E.2    Konijn, A.M.3    Fibach, E.4
  • 35
    • 14744278436 scopus 로고    scopus 로고
    • Anemia of chronic disease
    • 15758012 10.1056/NEJMra041809 1:CAS:528:DC%2BD2MXit1Wkt7Y%3D
    • Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-23.
    • (2005) N Engl J Med , vol.352 , pp. 1011-1023
    • Weiss, G.1    Goodnough, L.T.2
  • 36
    • 0036232280 scopus 로고    scopus 로고
    • Anemia management in chronic kidney disease: Role of factors affecting epoetin responsiveness
    • 11961032 10.1097/01.ASN.0000016440.52271.F7
    • Eschbach JW. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol. 2002;13:1412-4.
    • (2002) J Am Soc Nephrol , vol.13 , pp. 1412-1414
    • Eschbach, J.W.1
  • 37
    • 2542454908 scopus 로고    scopus 로고
    • Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis
    • 15168383 10.1053/j.ajkd.2004.02.016 1:CAS:528:DC%2BD2cXltlGjs7w%3D
    • Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, Izumi M, Takamitsu Y. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis. 2004;43:1030-9.
    • (2004) Am J Kidney Dis , vol.43 , pp. 1030-1039
    • Otaki, Y.1    Nakanishi, T.2    Hasuike, Y.3    Moriguchi, R.4    Nanami, M.5    Hama, Y.6    Izumi, M.7    Takamitsu, Y.8
  • 39
    • 0037926880 scopus 로고    scopus 로고
    • Cytokine-mediated regulation of iron transport in human monocytic cells
    • 12522003 10.1182/blood-2002-08-2459 1:CAS:528:DC%2BD3sXktVGmsro%3D
    • Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003;101:4148-54.
    • (2003) Blood , vol.101 , pp. 4148-4154
    • Ludwiczek, S.1    Aigner, E.2    Theurl, I.3    Weiss, G.4
  • 41
    • 0035902605 scopus 로고    scopus 로고
    • Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice
    • 11447267 10.1073/pnas.151179498 1:CAS:528:DC%2BD3MXls1Witbs%3D
    • Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 2001;98:8780-5.
    • (2001) Proc Natl Acad Sci USA , vol.98 , pp. 8780-8785
    • Nicolas, G.1    Bennoun, M.2    Devaux, I.3    Beaumont, C.4    Grandchamp, B.5    Kahn, A.6    Vaulont, S.7
  • 42
    • 0035896581 scopus 로고    scopus 로고
    • A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload
    • 11113132 10.1074/jbc.M008923200 1:CAS:528:DC%2BD3MXitFKhtbs%3D
    • Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811-9.
    • (2001) J Biol Chem , vol.276 , pp. 7811-7819
    • Pigeon, C.1    Ilyin, G.2    Courselaud, B.3    Leroyer, P.4    Turlin, B.5    Brissot, P.6    Loreal, O.7
  • 43
    • 10844258104 scopus 로고    scopus 로고
    • Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
    • 15514116 10.1126/science.1104742 1:CAS:528:DC%2BD2cXhtVOjsL3K
    • Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-3.
    • (2004) Science , vol.306 , pp. 2090-2093
    • Nemeth, E.1    Tuttle, M.S.2    Powelson, J.3    Vaughn, M.B.4    Donovan, A.5    Ward, D.M.6    Ganz, T.7    Kaplan, J.8
  • 44
    • 79953223315 scopus 로고    scopus 로고
    • Intestinal DMT1 cotransporter is downregulated by hepcidin via proteasome-internalization and degradation
    • 21199652 10.1053/j.gastro.2010.12.037 1:CAS:528:DC%2BC3MXjvVOkt74%3D
    • Brasse-Lagnel C, Karim Z, Letteron P, Bekri S, Bado A, Beaumont C. Intestinal DMT1 cotransporter is downregulated by hepcidin via proteasome-internalization and degradation. Gastroenterology. 2011;140:1261-71.
    • (2011) Gastroenterology , vol.140 , pp. 1261-1271
    • Brasse-Lagnel, C.1    Karim, Z.2    Letteron, P.3    Bekri, S.4    Bado, A.5    Beaumont, C.6
  • 46
    • 70349245261 scopus 로고    scopus 로고
    • Serum hepcidin concentration in chronic haemodialysis patients: Associations and effects of dialysis, iron and erythropoietin therapy
    • 19563467 10.1111/j.1365-2362.2009.02182.x 1:CAS:528:DC%2BD1MXhtlWhsrvI
    • Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, Kobold U, Mayer G. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39:883-90.
    • (2009) Eur J Clin Invest , vol.39 , pp. 883-890
    • Weiss, G.1    Theurl, I.2    Eder, S.3    Koppelstaetter, C.4    Kurz, K.5    Sonnweber, T.6    Kobold, U.7    Mayer, G.8
  • 47
    • 77957588960 scopus 로고    scopus 로고
    • Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients
    • 20668427 10.1038/ki.2010.254 1:CAS:528:DC%2BC3cXht1WmtLnO
    • Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010;78:769-73.
    • (2010) Kidney Int , vol.78 , pp. 769-773
    • Ford, B.A.1    Eby, C.S.2    Scott, M.G.3    Coyne, D.W.4
  • 48
    • 2342510407 scopus 로고    scopus 로고
    • IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
    • 15124018 1:CAS:528:DC%2BD2cXjvVOqsrY%3D
    • Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-6.
    • (2004) J Clin Invest , vol.113 , pp. 1271-1276
    • Nemeth, E.1    Rivera, S.2    Gabayan, V.3    Keller, C.4    Taudorf, S.5    Pedersen, B.K.6    Ganz, T.7
  • 49
    • 77957166516 scopus 로고    scopus 로고
    • Importance of ferritin for optimizing anemia therapy in chronic kidney disease
    • 20881381 10.1159/000320733 1:CAS:528:DC%2BC3cXhsVekt7zN
    • Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32:439-46.
    • (2010) Am J Nephrol , vol.32 , pp. 439-446
    • Nakanishi, T.1    Kuragano, T.2    Nanami, M.3    Otaki, Y.4    Nonoguchi, H.5    Hasuike, Y.6
  • 54
    • 0024446959 scopus 로고
    • Food iron absorption in idiopathic hemochromatosis
    • 2804357 1:STN:280:DyaK3c%2FivVOmsA%3D%3D
    • Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood. 1989;74:2187-93.
    • (1989) Blood , vol.74 , pp. 2187-2193
    • Lynch, S.R.1    Skikne, B.S.2    Cook, J.D.3
  • 56
    • 0016138423 scopus 로고
    • Serum ferritin as a measure of iron stores in normal subjects
    • 4472911 1:CAS:528:DyaE2cXkvFShsrk%3D
    • Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr. 1974;27:681-7.
    • (1974) Am J Clin Nutr , vol.27 , pp. 681-687
    • Cook, J.D.1    Lipschitz, D.A.2    Miles, L.E.3    Finch, C.A.4
  • 57
    • 63649105326 scopus 로고    scopus 로고
    • Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men
    • 19211819 10.3945/ajcn.2008.27297 1:CAS:528:DC%2BD1MXjslSks7g%3D
    • Roe MA, Collings R, Dainty JR, Swinkels DW, Fairweather-Tait SJ. Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men. Am J Clin Nutr. 2009;89:1088-91.
    • (2009) Am J Clin Nutr , vol.89 , pp. 1088-1091
    • Roe, M.A.1    Collings, R.2    Dainty, J.R.3    Swinkels, D.W.4    Fairweather-Tait, S.J.5
  • 58
    • 0024348472 scopus 로고
    • Model of reticuloendothelial iron metabolism in humans: Abnormal behavior in idiopathic hemochromatosis and in inflammation
    • 2502204 1:CAS:528:DyaL1MXlslWltLg%3D
    • Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood. 1989;74:844-51.
    • (1989) Blood , vol.74 , pp. 844-851
    • Fillet, G.1    Beguin, Y.2    Baldelli, L.3
  • 60
    • 84863070053 scopus 로고    scopus 로고
    • Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients?
    • 20797577 10.1053/j.jrn.2010.06.006
    • Brǎtescu LO, Bârsan L, Munteanu D, Stancu S, Mircescu G. Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients? J Ren Nutr. 2010;20:S77-83.
    • (2010) J Ren Nutr , vol.20
    • Brǎtescu, L.O.1    Bârsan, L.2    Munteanu, D.3    Stancu, S.4    Mircescu, G.5
  • 61
    • 78651386209 scopus 로고    scopus 로고
    • Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
    • 20962740 10.1038/ki.2010.382 1:CAS:528:DC%2BC3MXlsFKrtA%3D%3D
    • Hasegawa T, Bragg-Gresham JL, Pisoni RL, Robinson BM, Fukuhara S, Akiba T, Saito A, Kurokawa K, Akizawa T. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int. 2011;79:340-6.
    • (2011) Kidney Int , vol.79 , pp. 340-346
    • Hasegawa, T.1    Bragg-Gresham, J.L.2    Pisoni, R.L.3    Robinson, B.M.4    Fukuhara, S.5    Akiba, T.6    Saito, A.7    Kurokawa, K.8    Akizawa, T.9
  • 62
    • 13844254456 scopus 로고    scopus 로고
    • Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients
    • Japanese Society for Dialysis Therapy 10.1111/j.1774-9987.2004.00199.x
    • Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, Nishi S, Tsubakihara Y, Hirakata H, Bessho M, Japanese Society for Dialysis Therapy. Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2004;2004(8):443-59.
    • (2004) Ther Apher Dial , vol.2004 , Issue.8 , pp. 443-459
    • Gejyo, F.1    Saito, A.2    Akizawa, T.3    Akiba, T.4    Sakai, T.5    Suzuki, M.6    Nishi, S.7    Tsubakihara, Y.8    Hirakata, H.9    Bessho, M.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.